| Albumin usage in clinical medicine: tradition or therapeutic? A Farrugia Transfusion medicine reviews 24 (1), 53-63, 2010 | 269 | 2010 |
| Payment, compensation and replacement–the ethics and motivation of blood and plasma donation A Farrugia, J Penrod, JM Bult Vox sanguinis 99 (3), 202-211, 2010 | 157 | 2010 |
| Economic considerations on transfusion medicine and patient blood management A Hofmann, S Ozawa, A Farrugia, SL Farmer, A Shander Best practice & research Clinical anaesthesiology 27 (1), 59-68, 2013 | 133 | 2013 |
| Residual risk of transfusion‐transmitted viral infections in Shenzhen, China, 2001 through 2004 G Shang, CR Seed, F Wang, D Nie, A Farrugia Transfusion 47 (3), 529-539, 2007 | 130 | 2007 |
| A study of reported factor VIII use around the world JS Stonebraker, M Brooker, RE Amand, A Farrugia, A Srivastava Haemophilia 16 (1), 33-46, 2010 | 94 | 2010 |
| External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection F Ala, JP Allain, I Bates, K Boukef, F Boulton, J Brandful, EM Dax, ... Public Library of Science 9 (9), e1001309, 2012 | 91 | 2012 |
| The impact of the SARS‐CoV‐2 outbreak on the safety and availability of blood transfusions in Italy M Franchini, A Farrugia, C Velati, A Zanetti, L Romanò, G Grazzini, ... Vox Sanguinis 115 (8), 603, 2020 | 81 | 2020 |
| The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia F Yao, C Seed, A Farrugia, D Morgan, S Cordner, D Wood, MH Zheng American Journal of Transplantation 7 (12), 2723-2726, 2007 | 73 | 2007 |
| Intravenous immunoglobulin: regulatory perspectives on use and supply A Farrugia, P Poulis Transfusion Medicine 11 (2), 63-74, 2001 | 73 | 2001 |
| Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half‐strength citrate anticoagulant C Prowse, YG Waterston, J Dawes, A Farrugia Vox sanguinis 52 (4), 257-264, 1987 | 69 | 1987 |
| A comparative study using immunological and biological assays of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men CV Prowse, A Farrugia, FE Boulton, J Tucker, CA Ludlam, M McLaren, ... Thrombosis and haemostasis 51 (01), 110-114, 1984 | 66 | 1984 |
| Plasma fractionation issues A Farrugia, T Evers, PF Falcou, T Burnouf, L Amorim, S Thomas Biologicals 37 (2), 88-93, 2009 | 64 | 2009 |
| Treatment for life for severe haemophilia A–A cost‐utility model for prophylaxis vs. on‐demand treatment A Farrugia, J Cassar, MC Kimber, M Bansal, K Fischer, G Auserswald, ... Haemophilia 19 (4), e228-e238, 2013 | 60 | 2013 |
| Plasma for fractionation: safety and quality issues A Farrugia Haemophilia 10 (4), 334-340, 2004 | 60 | 2004 |
| Plasma protein therapies: current and future perspectives A Farrugia, P Robert Best Practice & Research Clinical Haematology 19 (1), 243-258, 2006 | 50 | 2006 |
| The mantra of blood safety: time for a new tune? A Farrugia Vox sanguinis 86 (1), 1-7, 2004 | 39 | 2004 |
| Relative survival benefit and morbidity with fluids in severe sepsis-a network meta-analysis of alternative therapies M Bansal, A Farrugia, S Balboni, G Martin Current drug safety 8 (4), 236-245, 2013 | 38 | 2013 |
| Globalisation and blood safety A Farrugia Blood Reviews 23 (3), 123-128, 2009 | 38 | 2009 |
| Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment I Quinti, F Pulvirenti, C Milito, G Granata, G Giovannetti, F La Marra, ... Transfusion 55 (5), 1067-1074, 2015 | 36 | 2015 |
| Evolving perspectives in product safety for haemophilia A Farrugia Haemophilia 8 (3), 236-243, 2002 | 36 | 2002 |
Isabella QuintiProfessor of Internal Medicine, Immunology, Sapienza University of Rome, Italy在 uniroma1.it 的电子邮件经过验证
